HRTX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
37.7M
+8.5%
34.7M
-14.5%
40.6M
+6.2%
38.2M
+2.7%
37.2M
Cost of Revenue
11.6M
+8.8%
10.6M
-4.3%
11.1M
-6.7%
11.9M
+20.9%
9.9M
Gross Profit
26.1M
+8.4%
24.1M
-18.3%
29.5M
+12.1%
26.3M
-3.8%
27.3M
Operating Expenses
28.1M
-2.4%
28.8M
-2.0%
29.4M
-3.2%
30.4M
+4.9%
29.0M
R&D
2.7M
+13.3%
2.4M
-36.3%
3.7M
+8.0%
3.5M
+18.3%
2.9M
SG&A
25.4M
-3.8%
26.5M
+3.0%
25.7M
-4.6%
26.9M
+3.4%
26.0M
Operating Income
-2044000
+57.1%
-4765000
-12639.5%
38.0K
+100.9%
-4093000
-150.0%
-1637000
EBITDA
-1592000
+62.4%
-4236000
-836.7%
575.0K
+116.5%
-3478000
-239.0%
-1026000
Net Income
-5489000
+32.3%
-8111000
-174.6%
-2954000
+83.1%
-17495000
-634.8%
-2381000
EPS (Basic)
$-0.03
+25.0%
$-0.04
-100.0%
$-0.02
+80.0%
$-0.10
-400.0%
$-0.02
EPS (Diluted)
$-0.03
+25.0%
$-0.04
-100.0%
$-0.02
+80.0%
$-0.10
-400.0%
$-0.02
Shares (Diluted)
190.3M
+0.4%
189.6M
+30.3%
145.5M
-14.6%
170.3M
+10.6%
154.0M
Heron Therapeutics (HRTX) โ€” Financials